학술논문

The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology
Document Type
article
Source
Alzheimer's & Dementia. 16(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Alzheimer's Disease Related Dementias (ADRD)
Neurosciences
Dementia
Brain Disorders
Rare Diseases
Alzheimer's Disease
Acquired Cognitive Impairment
Genetics
Aging
Neurodegenerative
Clinical Trials and Supportive Activities
Frontotemporal Dementia (FTD)
Neurological
Adult
C9orf72 Protein
Female
Frontotemporal Dementia
Genetic Predisposition to Disease
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Mutation
Neuropsychological Tests
tau Proteins
C9orf72
Frontotemporal dementia
GRN
MAPT
Tau
TDP-43
LEFFTDS Consortium
Geriatrics
Clinical sciences
Biological psychology
Language
Abstract
IntroductionIt is important to establish the natural history of familial frontotemporal lobar degeneration (f-FTLD) and provide clinical and biomarker data for planning these studies, particularly in the asymptomatic phase.MethodsThe Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects protocol was designed to enroll and follow at least 300 subjects for more than at least three annual visits who are members of kindreds with a mutation in one of the three most common f-FTLD genes-microtubule-associated protein tau, progranulin, or chromosome 9 open reading frame 72.ResultsWe present the theoretical considerations of f-FTLD and the aims/objectives of this protocol. We also describe the design and methodology for evaluating and rating subjects, in which detailed clinical and neuropsychological assessments are performed, biofluid samples are collected, and magnetic resonance imaging scans are performed using a standard protocol.DiscussionThese data and samples, which are available to interested investigators worldwide, will facilitate planning for upcoming disease-modifying therapeutic trials in f-FTLD.